SEC Form 5 · accession 0001209191-17-014930
AERIE PHARMACEUTICALS INC · AERI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Casey C. Kopczynski
Officer — Chief Scientific Officer
Period of report
Dec 31, 2016
Accepted (ET)
Feb 27, 2017 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001337553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2015 | M | 4,596 | $0.005 | A | 182,675 | D | |
| Common Stock | Feb 25, 2016 | F | 692 | $16.34 | D | 181,983 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.005 | Jun 15, 2015 | M | 4,596 | D | — | Aug 12, 2015 | Common Stock | 4,596 | 0 | D |
Explanation of responses
- F1This option was fully vested and exercisable.